Abstract
Introduction
Methods
Results
Conclusion
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerREFERENCES
- Cancer statistics, 2018.CA Cancer J Clin. 2018; 68: 7-30
- Epidemiology of renal cell carcinoma [figure presented].Eur Urol [Internet]. 2019; 75: 74-84https://doi.org/10.1016/j.eururo.2018.08.036
- Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.J Urol [Internet]. 2010; 183: 1309-1316https://doi.org/10.1016/j.juro.2009.12.035
- A postoperative prognostic nomogram for renal cell carcinoma.J Urol. 2001; 166: 63-67
- Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria.Cancer. 2013; 119: 2999-3006
- Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1116-1127
- Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma.N Engl J Med. 2018; 378: 1277-1290
- Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2021; 384: 829-841
- Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 1.Ann Oncol. 2021; 32: 422-423
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial.Lancet Oncol [Internet]. 2016; 17 (Available from:): 378-388https://doi.org/10.1016/S1470-2045(15)00515-X
- Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (espn): a randomized multicenter phase 2 trial.Eur Urol [Internet]. 2016; 69: 866-874https://doi.org/10.1016/j.eururo.2015.10.049
Evans AE, Angio GJD, Sather HN. Median Follow-Up in Clinical Trials. 2019;191–2.
- The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours.Eur Urol [Internet]. 2016; 70: 93-105https://doi.org/10.1016/j.eururo.2016.02.029
- Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.J Clin Oncol. 2002; 20: 2376-2381
- Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.Ann Oncol. 2017; 28: 1339-1345
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 706-720
- Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma.J Clin Oncol. 2021; 39: 1029-1039
- Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.J Immunother Cancer. 2018; 6: 1-7
- Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis.Oncologist. 2020; 25: 252-258
- Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.J Clin Oncol. 2021; 39: 309
- Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.Eur J Cancer. 2022; 171: 124-132
- Systemic therapy for chromophobe renal cell carcinoma: a systematic review.Urol Oncol. 2020; 38: 137-149https://doi.org/10.1016/j.urolonc.2019.11.006
- Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates.J Clin Oncol. 2022; 40: 2333-2341
- Sarcoma: Concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.Ann Oncol [Internet]. 2012; 23 (Available from:): 2442-2449https://doi.org/10.1093/annonc/mdr610
Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia [Internet]. Vol. 34, Modern Pathology. Springer US; 2021. 1392–1424 p. Available from: 10.1038/s41379-021-00779-w
Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A. Original report abstract comprehensive genomic analysis of metastatic non – clear-cell renal cell carcinoma to identify therapeutic targets. 2020;1–18.
- Non-clear cell renal carcinomas: review of new molecular insights and recent clinical data.Cancer Treat Rev. 2021; 97
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.Lancet [Internet]. 2021; 397 (Available from): 695-703https://doi.org/10.1016/S0140-6736(21)00152-5
- Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Nat Commun [Internet]. 2016; 7: 1-10https://doi.org/10.1038/ncomms13131
- Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling.Eur Urol [Internet]. 2016; 70: 516-521https://doi.org/10.1016/j.eururo.2015.06.019
- Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.J Clin Oncol. 2020; 38: 5004
- Kidney cancer: from genes to therapy.Curr Probl Cancer [Internet]. 2021; 45 (Available from:)100773https://doi.org/10.1016/j.currproblcancer.2021.100773
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.J Clin Oncol. 2009; 27: 5794-5799
- Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study.Cancer Res Treat. 2018; 50: 488-494
- KEYNOTE-B61: open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).J Clin Oncol. 2021; 39: TPS4595
- Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival.JAMA Netw Open. 2021; 4: 1-11
- Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial.Eur J Cancer. 2020; 129: 107-116
- First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: A phase II study (SUPAP) by the French Genitourinary Group (GETUG).Ann Oncol. 2015; 26: 1123-1128
- Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.Eur J Cancer. 2016; 69: 226-235
- Efficacy of savolitinib vs sunitinib in patients with MET -driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 1247-1255
- Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features.J Clin Oncol. 2020; 38: 63-70